Mylan gets topicals CDMO as part of $1B deal for skin products

Mylan corporate campus
Mylan corporate campus

Mylan ($MYL) has struck a $1 billion deal to get the dermatology business of Renaissance Acquisition Holding. But it is getting more than a portfolio of generic meds; it is also getting two plants and the contract manufacturing business they do.

On Friday, Mylan said it will pay $950 million in cash and up to $50 million in additional payments for the nonsterile, topicals-focused specialty and generics business of Renaissance, a fund that invests in pharma assets. It gets about 1,200 workers, including employees on both the sales and manufacturing side of the business. It said the businesses it is getting had 2015 revenues of about $370 million. Mylan wouldn't break out how much of that business is from the CDMO.

Mylan said the two manufacturing sites are located in Montreal, Canada, and San Antonio, TX, and have capabilities and capacity in creams, ointments, aerosols/foams, gels, suspensions, liquids and suppositories. It said the operations were complementary to Mylan's existing capabilities, suggesting it would keep them when the deal is complete.

Renaissance, which is privately controlled and majority-owned by RoundTable Healthcare Partners, was started in 2010 when Roundtable acquired Montreal, Canada-based Confab Laboratories and DPT Laboratories, which was based in San Antonio, TX.


The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

The two companies said that RoundTable will keep its sterile-focused businesses and the manufacturing facility that produces those products. Mylan already has its hands full with Agila Specialties. It bought Agila from India’s Stride in 2013 for $1.6 billion and then ran into FDA issues over several of the plants. 

Mylan is also getting more manufacturing capacity as part of the $7.2 billion deal it announced in February to buy Sweden-based Meda. In that deal, which is expected to close by the end of Q3 2016, Mylan is picking up 7 more manufacturing facilities in Europe, the U.S. and India.

- read the Mylan announcement
- here’s the RoundTable announcement 

Related Articles:
Mylan snaps up dermatology biz from investors in $1B deal 
Mylan snags Meda, advances its OTC ambitions, with $7.2B deal 
Mylan expands recalls from plants spanked in FDA warning letter 
Mylan snags Meda, advances its OTC ambitions, with $7.2B deal

Suggested Articles

The FDA lambasted Strides Pharma in a warning letter after inspectors found testing records in the trash and in bags by a shredder.

Chinese biotech CMBG hopes to get a cell manufacturing facility built in nine months and more manufacturing news of note.

Kite has been buying the viral vector starting material for its CAR-T treatment Yescarta from contractors but says it is time to produce its own.